A Phase Ia, Dose-Escalating, Safety and Immunogenicity Trial of the Monovalent Zaire Ebola Viral Vector Candidate Vaccine cAd3-EBO Z and the Heterologous Prime-boost Candidate Vaccine Regimen cAd3-EBO Z and MVA-BN® Filo in Healthy UK Adults
Active, no longer recruiting
Phase of Trial: Phase I
Latest Information Update: 22 Jun 2017
At a glance
- Drugs GSK 3390107A (Primary) ; Modified Vaccinia Ankara Bavarian Nordic Ebola Marburg vaccine (Primary)
- Indications Ebola virus infections
- Focus Adverse reactions; First in man
- Acronyms OXFORD
- 19 Jun 2017 Planned End Date changed from 1 Mar 2017 to 1 Aug 2017.
- 19 Jun 2017 Planned primary completion date changed from 1 Mar 2017 to 1 Aug 2017.
- 19 Jun 2017 Status changed from recruiting to active, no longer recruiting.